Grey Wolf HealthTSXV:WOLF 52 EV-to-FCF is 20.10 as of Jul. 08, 2026, which is 1% above its 10-year median of 19.96. GuruFocus rates TSXV:WOLF with a GF Score™ of 52/100 and a GF Value™ of C$1.10 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 563 Drug Manufacturers companies, Grey Wolf Health ranks better than 52.93% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Grey Wolf Health's Enterprise Value is C$77.58 Mil.
Grey Wolf Health's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was C$3.86 Mil. Therefore, Grey Wolf Health's EV-to-FCF for today is 20.10.
The historical rank and industry rank for Grey Wolf Health's EV-to-FCF or its related term are showing as below:
TSXV:WOLF'
s EV-to-FCF Range Over the Past 10 Years
Min: -47.42 Med: 19.96 Max: 143.67
Current: 19.84
During the past 5 years, the highest EV-to-FCF of Grey Wolf Health was 143.67. The lowest was -47.42. And the median was 19.96.
TSXV:WOLF's EV-to-FCF is ranked better than 52.93% of 563
companies
in the Drug Manufacturers industry
Industry Median: 20.85
vs TSXV:WOLF: 19.84
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Grey Wolf Health (TSXV:WOLF) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Grey Wolf Health's PE Ratio (TTM) for today is calculated as:
Grey Wolf Health's share price for today is C$1.78.
Grey Wolf Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.054.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Grey Wolf Health EV-to-FCF Related Terms
Grey Wolf Health EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Grey Wolf Health's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Grey Wolf Health's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grey Wolf Health EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grey Wolf Health's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Grey Wolf Health's EV-to-FCF falls into.
Grey Wolf Health's current Enterprise Value is C$77.58 Mil.
Grey Wolf Health's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$3.86 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grey Wolf Health (TSXV:WOLF) has a EV-to-FCF of 20.10 as of Jul. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Grey Wolf Health and its competitors. This is near median its historical median of 19.96. According to the industry distribution chart, Grey Wolf Health ranks #265 out of 563 companies in the Drug Manufacturers industry, placing it in the top 47.1%.
Is Grey Wolf Health's EV-to-FCF too high?
Grey Wolf Health's current EV-to-FCF of 20.10 is near median its 10-year median of 19.96. The Drug Manufacturers industry median EV-to-FCF is 20.85. Grey Wolf Health's value of 20.10 is 3.6% below this industry median. Based on the distribution chart, Grey Wolf Health ranks #265 out of 563 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Grey Wolf Health has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Grey Wolf Health's EV-to-FCF compare to ROL and SCI?
According to the Drug Manufacturers industry distribution chart, Grey Wolf Health ranks #265 out of 563 companies for EV-to-FCF. This puts Grey Wolf Health in the upper half of its industry. The industry median EV-to-FCF is 20.85. Grey Wolf Health's value of 20.10 is 3.6% below this benchmark. While the company's 10-year median is 19.96 vs. the industry median of 20.85, Grey Wolf Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.85, based on 563 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grey Wolf Health's current EV-to-FCF of 20.10 is 3.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Grey Wolf Health and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grey Wolf Health's current EV-to-FCF is 20.10, which is near median its own 10-year median of 19.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grey Wolf Health stock overvalued right now?
Based on GuruFocus' analysis, Grey Wolf Health (TSXV:WOLF) is currently considered Significantly Overvalued. The stock's GF Value™ is C$1.10, compared to a current price of C$1.78 — trading 61.8% above its estimated fair value. The current EV-to-FCF is 20.10, which is near median its 10-year median of 19.96 and 3.6% below the Drug Manufacturers industry median of 20.85. Grey Wolf Health's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Grey Wolf Health (TSXV:WOLF), the current EV-to-FCF is 20.10 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grey Wolf Health (TSXV:WOLF) Overvalued in 2026?
Based on GuruFocus' analysis, Grey Wolf Health stock appears to be overvalued.
The current stock price of C$1.78 is trading 61.8% above its estimated GF Value™ of C$1.10.
GuruFocus considers Grey Wolf Health to be Significantly Overvalued.
Key valuation signals for TSXV:WOLF:
EV-to-FCF: 20.10 (near median its 10-year median of 19.96)
GF Value™: C$1.10 vs. price of C$1.78 (61.8% above fair value)
Industry Position: 3.6% below the Drug Manufacturers median (#265 of 563)
No single metric tells the full story. See the TSXV:WOLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grey Wolf Animal Health Corp focuses on sourcing, in-licensing, acquiring, and compounding branded and generic products for sale in both animal and human health markets in Canada. The Company operates through two reportable segments: the Animal Health segment, which involves the sale, marketing, and distribution of pharmaceutical, nutraceutical, and consumable products to veterinary clinics across Canada; and the Pharmacy segment, which generates the majority of revenue and focuses on compounding pharmaceuticals for both human and animal health markets.
52GF Score
Get the complete analysis for TSXV:WOLF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:WOLF has been successfully added to your 
